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Outcome of weekly carboplatin-paclitaxel based definitive chemoradiation in oesophageal cancer, in 
patients not considered suitable for platinum-fluoropyrimidine based treatment: a multi-centre, 
retrospective review. 
 
Abstract 
Background 
Although cisplatin-fluoropyrimidine (CF) based definitive chemoradiotherapy (dCRT) is a standard of 
care for oesophageal cancer, toxicity is significant and limits its use in elderly and frail patients. The 
weekly carboplatin/paclitaxel (wCP) based dCRT provides a viable alternative, although prospective 
data is lacking in the dCRT setting.  
Methods 
In this multicentre retrospective study from 9 radiotherapy centres across the United Kingdom, we 
evaluated outcome in patients who had non-metastatic, histologically confirmed carcinoma of the 
oesophagus (adenocarcinoma, squamous-cell, or undifferentiated; WHO performance status 0–2; stage 
I–III disease) and had been selected to receive wCP based dCRT as they were considered not suitable 
for CF dCRT. dCRT consisted of Carboplatin AUC 2 and Paclitaxel 50mg/ m2 (days 1,8,15,22,29) and 
the recommended radiation dose was 50Gy in 25 daily fractions. We assessed overall survival (OS), 
progression free survival (overall, local and distant) (PFS), proportion of patients failure-free at 
response assessment (12 weeks post dCRT), treatment compliance and toxicity.  
Findings 
 
214 patients from 9 UK centres were treated between Feb 15, 2013, and March 19, 2019. 39.7% of 
patients were ≥75yrs ; 18.7% ≥80 yrs. Indications for wCP dCRT were co-morbidities (47.2%), 
clinician choice (36.4%) and poor tolerance/progression on CF induction chemo (15.8%). Median OS 
was 24.28 months (95% CI: 20.07-30.09) and median PFS was 16.33 months (95% CI: 14.29-20.96).  
Following treatment, 69.1% (96/139) had combined complete response (CR) on endoscopy with non-
progression (CR/partial response (PR)/stable disease (SD)) on imaging. The 1-year and 2-year OS for 
this patient group was 81.9% (95% CI: 75.6%-86.8%) and 50.6% (95% CI: 40.5%-60.0%) respectively.  
33% (n=70) of patients experienced at least one grade 3+ acute toxicity (Grade 3/4 haematological:10%; 
grade 3/4 non-haematological:32%) and there were no treatment related deaths. 86.9% of patients 
completed at least 4 cycles of concomitant wCP chemotherapy and planned radiotherapy was completed 
in 97.7% (209/214).  
 
Conclusion 
 
 
Weekly carboplatin-paclitaxel based chemoradiotherapy appears to be well tolerated in elderly patients 
and in those with co-morbidities, where CF-based dCRT is contra-indicated. Survival outcomes are 
comparable to CF-based dCRT. 
 
 
Introduction 
Definitive chemoradiotherapy (dCRT), usually consisting of radiation dose 50-64 Gray (Gy) in 1.8-2Gy 
per fraction, is a treatment option for patients with localised oesophageal cancer, particularly squamous 
cell cancers (SCC) and in patients [both SCC and adenocarcinoma (ACA)] where surgery is considered 
inappropriate due to patient’s co-morbidities or disease extent. Traditionally, a combination of cisplatin 
with 5FU (or capecitabine) (CF), has formed the chemotherapy backbone i,ii, but more recently a 
combination of weekly carboplatin-paclitaxel (wCP) has been reported in retrospective studies to 
demonstrate comparable efficacy to cisplatin–fluoropyrimidine (CF) with better tolerance and lower 
incidence of grade 3-4 toxicityiii. This regimen, originally reported in the neo-adjuvant setting in the 
CROSS trialiv, demonstrated a low incidence of Grade 3-4 toxicity (hematological 8%; non-
hematological 13%) and has therefore allowed physicians to treat with radical intent, patients who 
would have otherwise been considered unfit for radical treatment – mainly those with poor performance 
status or elderly patients who are unlikely to withstand the traditional CF radiation combination.  
In the UK, a national survey of upper GI oncologists demonstrated that whilst the majority of 
oncologists still favoured the CF based dCRT for patients who were fit enough to receive it, wCP dCRT 
was commonly offered in patients where CF-dCRT was contraindicated because of age, frailty or 
medical comorbidities.  Herein we report the results of a national, multi-centre retrospective review of 
outcome in patients treated with wCP based dCRT.  
 
Methods 
Study design and patients 
In this multi-centre retrospective study, we included patients from radiotherapy (RT) centres across the 
UK who met the following key eligibility criteria: non-metastatic, histologically confirmed carcinoma 
of the oesophagus or gastro-oesophageal junction (GOJ), WHO performance status 0-2, stage I-III 
disease and who, in the opinion of the treating clinician, were not suitable for CF-based dCRT. The RT 
centres were primarily identified based on the respondents of a national surveyv.. 
Patients were staged in accordance with local protocols, which in the UK, consists of contrast-enhanced 
spiral CT scan of thorax and abdomen, 18F-fluorodeoxyglucose CT-PET (PET-CT), endoscopic 
 
ultrasound where feasible, and optional laparoscopy in patients with tumour extending below the 
diaphragm.  
 
Treatment and follow up 
Chemotherapy consisted of weekly carboplatin (AUC2) and paclitaxel (50mg/m2) given intravenously 
concurrent with radiotherapy. Patients who had received induction chemotherapy prior to start of wCP 
dCRT were also included in the study. Dose modification for toxicity was as the discretion of treating 
clinician. 
RT was delivered as per local protocol. The usual dose of radiation was 50Gy in 25 fractions, delivered 
Monday to Friday as three-dimensional (3D) conformally planned or intensity modulated (including 
volumetric arc) radiotherapy. Follow up assessment included a CT scan (or PET-CT, depending on 
centre choice) at 12 weeks following completion of dCRT; endoscopic assessment of response was also 
routinely conducted in 7 of 9 centres which contributed to this study. Subsequent follow up was as per 
centre choice, but data was collected on overall survival, progression free survival, site of disease 
relapse and acute toxicity. 
Endpoints were overall survival, progression free survival (overall, local and distant), proportion of 
patients failure-free at response assessment (12 weeks post dCRT), treatment compliance and acute 
toxicity.  
Statistical analysis 
All statistical analyses were conducted using the Stata 14 statistical package according to a pre-specified 
analysis plan.  Survival was calculated from the date of diagnosis to when an event occurred, that is, 
any death for overall survival (OS), and local/distant progression or any death for local/metastasis 
progression free survival (PFS).  Local PFS was defined as the time to progression within the 
radiotherapy field (with or without metastatic disease) or death due to any cause. Distant PFS was 
defined as time to progression with metastases or death by any cause. Patients who were event free were 
censored at the time they were last known to be event free.  The Kaplan Meier method was used to 
derive estimates of event time distributions for OS and overall, local and distantPFS.  Hazard ratios 
from univariable and multivariable Cox regression models were assessed for OS of all patients and also 
for patients that reached and received the post treatment endoscopy (the proportional hazards 
assumption for each model was tested using Cox-Snell residuals and Schoenfeld’s global test).   
The multivariable Cox regression models included Age (<75 vs ≥75), Sex (Female vs Male), WHO PS 
(0 vs 1-2), T stage (1-2 vs 3-4), N stage (0 vs 1+), Induction chemo (Yes vs No), Histology (SCC vs 
Adeno), Site (middle/upper Third vs Lower Third), Post treatment response (Complete Response (CR) 
 
on endoscopy with CR/Stable disease (SD)/Partial response (PR) on imaging vs Others) and Disease 
length (continuous variable).  
Source of funding 
A Cancer Research UK programme grant for the Cardiff University Centre for Trials Research funded 
CH and CC. SM is part-funded by Oxford Biomedical Research Centre. The statisticians (CC, CH) had 
full access to all the data and the lead authors (RO, SM) and statisticians (CC, CH) had final 
responsibility for the decision to submit for publication. No authors expressed conflict of interest. 
Results 
Study population 
214 patients from 9 UK centres who received dCRT between Feb 15, 2013, and March 19, 2019, were 
included in the analysis.  Patient characteristics are described in Table 1.  In summary, median age was 
73 (range 42-91; 39.7% ≥75yrs; 18.7% >80 yrs), 65.0% (139/214) were male, only 29.0% (62/214) 
were WHO Performance Status 0, 57.5% (123/214) had adenocarcinoma and median disease length 
was 4.7cm (IQR: 3.0-6.5). 
Of the 214 patients, 38.3% (82/214) received induction chemotherapy.  Indications for wCP dCRT 
included co-morbidities (47.2%, n=101), clinician preference (36.4%, n=78) and poor 
tolerance/progression on CF induction chemo (15.8%, n=34).  During dCRT (Figure 1 and Table 1), 
the median percentage of dose of both carboplatin and paclitaxel was 100 (IQR: 80-100). 87.4% and 
62.1% of patients completed 4 and 5 cycles of carboplatin respectively, whilst 86.9% and 61.7% of 
patients completed 4 and 5 cycles of paclitaxel.  In 61.7% (n=132) of patients, radiation was planned 
using IMRT. The majority of patients were prescribed 50Gy/25 fractions or above (dose range 
41.4Gy/23fractions-64Gy/32 fractions with 2 patients being prescribed <50 Gy: 1 each were prescribed 
41.4Gy and 45Gy respectively and were included in the analysis as neither patient was fit for surgery). 
Planned radiotherapy was completed in 97.7% (209/214). 
The median duration of follow-up for surviving patients was 16.9 months (95% CI: 15.6, 19.5)). 
Toxicities 
All toxicities (graded as per CTCAE version 4) reported during dCRT are shown in Table 2.  During 
treatment 32.7% (n=70) of patients experienced at least one grade 3+ toxicity; 9.8% (n=21) had at least 
1 grade 3/4 haematological toxicity and 31.8% (n=68) had at least 1 grade 3/4 non-haematological 
toxicity.  The most common grade 3 non-haematological toxicities were nausea (6.1%, n=13) and 
vomiting (6.1%, n=13).  There were 2 recorded deaths during treatment (oesophageal haemorrhage, 
duodenal perforation) but these were not felt to be treatment related. There were 10 further deaths within 
90 days of treatment; 4 were due to progressive metastatic disease, 1 due to hospital acquired 
 
pneumonia, 1 due to pulmonary embolism, 1 to unrelated fall and head injury and 3 from unknown 
causes.    
Overall & Progression Free Survival 
Median overall survival was 24.3 months (95% CI: 20.07-30.09), demonstrated in Figure 2a.  The 1-
year and 2-year OS rates were 81.9% (95% CI: 75.6%-86.8%) and 50.6% (95% CI: 40.5%-60.0%) 
respectively. The univariable Cox proportional hazards regression models (Table 3) showed that the 
significant predictors of worse OS were higher N Stage (HR: 2.01 (95% CI: 1.20-3.36, p=0.008)), 
having induction chemotherapy (HR: 1.63 (95% CI: 1.03-2.56, p=0.037)) and disease length (HR 1.13 
(95% CI: 1.02-1.26,p=0.021)), but they were all statistically insignificant (p>0.05) after adjusting for 
baseline characteristics in the multivariable model.  In addition, whilst 36% of patients received 
carboplatin-paclitaxel chemotherapy based upon ‘clinician choice’, there was no statistically significant 
difference in OS between those patients, and those whose indication for carboplatin-paclitaxel was due 
to co-morbidities or poor tolerance/progression to induction chemotherapy.  
At the post-treatment response assessment, 139 patients had an endoscopy, 189 had cross-sectional 
imaging, and 12 patients had died prior to the assessment time point. 71.2% (99/139) had complete 
response (CR) on endoscopy defined as a negative biopsy, 86.2% (163/189) had non-progression 
(CR/Partial response (PR)/Stable disease (SD)) on imaging, and 72.1% (98/136) had combined CR on 
endoscopy with non-progression on imaging (in the cohort where both endoscopy and imaging 
available, n=136).  The OS analysis for patients that proceeded to post treatment endoscopy (139/214) 
(Table 4 and Figure 2b) showed that the median survival in patients that had complete response (CR) 
on the endoscopy plus non-progression on imaging, i.e. “treatment failure free” (98/139) was 30.1 
months (95% CI: 27.0-.), compared to 16.9 months (95% CI: 14.2-22.6) for those who did not i.e. “those 
with evidence of residual or progressive disease.  The 1-year and 2-year OS for patients that were 
”treatment failure free” were 92.2% (95% CI: 85.5%-95.8%) and 60.2% (95% CI: 47.3%-70.9%) 
respectively.  The hazard ratio for treatment failure free vs failure was significant in both univariable 
and multivariable analyses (3.86 (95% CI: 2.04-7.33, p<0.001) and 5.07 (95% CI: 2.11-12.21, p<0.001) 
respectively).  
Of the 214 patients treated, 33.2% (71/214) had progressed at the time of data collection, with 40.8% 
(29/71) of those being local, 52.1% (37/71) distant and 7.0% (5/71) both local and distant relapses 
(missing data, n=5).  Median PFS was 16.3 months (95% CI: 14.3-21.0), median local PFS was 20.1 
months (95% CI: 16.8-22.9) and median distant PFS was 21.0 months (95% CI: 16.7-30.1) (Figure 2c).  
 
  
Commented [MOU1]: In the patient with PE and 
Pneumonia, Do you know the approximate time point of 
death compared to completion of treatment (if they were 
say  >6 weeks after completion of treatment, we can say that 
these were unlikely to be direct consequences of treatment). 
The others are clearly not related. 
 
 
Figure 1 – Percent of total chemotherapy dose during CRT 
 
 
 
 
  
 
Figure 2 – Kaplan-Meier curves of overall and progression free survival 
(a) 
 
(b) 
 
(c) 
 
 
 
  
 
Table 1 – Patient characteristics and treatment 
 
 Characteristic   n % 
 Sex  
Male 139 65.0% 
Female 75 35.0% 
Age 
Median (IQR, range) 73 ((65,78), 42-91) 
70+ 134 62.6% 
80+ 40 18.7% 
T stage 
1 8 3.7% 
2 48 22.4% 
3 124 57.9% 
4 29 13.6% 
Missing 5 2.3% 
N stage 
0 97 45.3% 
1 80 37.4% 
2 32 15.0% 
3 5 2.3% 
Site 
Lower third/GOJ 123 57.5% 
Middle third 79 36.9% 
Upper third 12 5.6% 
Performance status 
0 62 29.0% 
1 124 57.9% 
2 23 10.7% 
Missing 5 2.3% 
Disease length Median (IQR, range) 4.7 ((3.0, 6.5), 1-13) 
Histology 
SCC 91 42.5% 
Adeno 123 57.5% 
Indication for carboplatin-
paclitaxel 
Co-morbidities precluding cisplatin/5-FU combination 101 47.2% 
Clinician choice  78 36.4% 
Poor tolerance to induction chemotherapy 17 7.9% 
Progression following induction chemotherapy 17 7.9% 
Missing 1 0.5% 
Induction chemotherapy 
Yes 82 38.3% 
No 132 61.7% 
RT planning 
Conformal 54 25.2% 
IMRT/Rapid arc 132 61.7% 
Missing 28 13.1% 
Radiotherapy regimen 
41.4Gy in 23# 1 0.5% 
45Gy in 25# 1 0.5% 
50Gy in 25# 179 83.6% 
50.4Gy in 28# 5 2.3% 
54Gy in 30# 21 9.8% 
60Gy in 30# 1 0.5% 
64Gy in 32# 1 0.5% 
Not completed* 5 2.3% 
Concurrent 
Carbolatin/Paclitaxel 
Carboplatin dose intensity (median, IQR, range) 100 ((80, 100), 0-100) 
Completed 4 cycles of Carboplatin 187 87.4% 
Completed 5 cycles of Carboplatin 133 62.1% 
Paclitaxel dose intensity (median, IQR, range) 100 ((80, 100), 0-100) 
Completed 4 cycles of Paclitaxel 186 86.9% 
Completed 5 cycles of Paclitaxel 132 61.7% 
Reasons for non-
completion of concurrent 
chemotherapy 
Nausea 8 3.7% 
Vomiting 6 2.8% 
Neutropenia 26 12.1% 
 
Carboplatin/Paclitaxel Infection 6 2.8% 
Dehydration 7 3.3% 
Diarrhoea  3 1.4% 
 Fatigue 3 1.4% 
Oesophagitis 4 1.9% 
Thrombocytopenia 11 5.1% 
Hypotension 2 0.9% 
Other 18 8.4% 
*1x21.6Gy, 2x36Gy, 1x48Gy, 1x48.6Gy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 2 – Toxicities during CRT (N=214)(CTCAE v4) 
Toxicity Grade 
(N=214) 1 % 2 % 3 % 4 % 5 % 
Blood/lymph               
Anaemia 16 7.5% 15 7.0% 3 1.4% 0 0.0% 0 0.0% 
Febrile Neutropenia 2 0.9% 9 4.2% 14 6.5% 0 0.0% 0 0.0% 
Neutropenia 4 1.9% 9 4.2% 5 2.3% 0 0.0% 0 0.0% 
GI disorders                     
Abdominal pain 1 0.5% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Constipation 13 6.1% 3 1.4% 2 0.9% 0 0.0% 0 0.0% 
Duodenal perforation 0 0.0% 0 0.0% 0 0.0% 0 0.0% 1 0.5% 
Diarrhoea 12 5.6% 5 2.3% 5 2.3% 0 0.0% 0 0.0% 
Dysphagia 8 3.7% 4 1.9% 1 0.5% 0 0.0% 0 0.0% 
Gastrointestinal haemorrhage 0 0.0% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Mucositis oral 1 0.5% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Nausea 30 14.0% 15 7.0% 13 6.1% 0 0.0% 0 0.0% 
Oesophagitis 36 16.8% 37 17.3% 12 5.6% 0 0.0% 0 0.0% 
Oesophageal pain 0 0.0% 4 1.9% 0 0.0% 0 0.0% 0 0.0% 
Oesophageal haemorrhage 0 0.0% 1 0.5% 0 0.0% 0 0.0% 1 0.5% 
Pancreatitis 0 0.0% 0 0.0% 1 0.5% 0 0.0% 0 0.0% 
Upper gastrointestinal haemorrhage 0 0.0% 0 0.0% 1 0.5% 0 0.0% 0 0.0% 
Vomiting 23 10.7% 6 2.8% 13 6.1% 0 0.0% 0 0.0% 
General disorders                     
Edema limbs 1 0.5% 0 0.0% 0 0.0% 0 0.0% 0 0.0% 
Fatigue 42 19.6% 25 11.7% 7 3.3% 0 0.0% 0 0.0% 
Pain 15 7.0% 11 5.1% 1 0.5% 0 0.0% 0 0.0% 
Infections                     
Infection 3 1.4% 8 3.7% 9 4.2% 0 0.0% 0 0.0% 
Joint infection 0 0.0% 0 0.0% 1 0.5% 0 0.0% 0 0.0% 
Sepsis (non-neutropenic) 0 0.0% 0 0.0% 2 0.9% 0 0.0% 0 0.0% 
Wound infection 0 0.0% 0 0.0% 1 0.5% 0 0.0% 0 0.0% 
Urinary tract infection 0 0.0% 0 0.0% 1 0.5% 0 0.0% 0 0.0% 
Investigations                     
Platelet count decreased 10 4.7% 7 3.3% 1 0.5% 0 0.0% 0 0.0% 
Weight loss 0 0.0% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Metabolism/nutrition                     
Anorexia 2 0.9% 3 1.4% 3 1.4% 1 0.5% 0 0.0% 
Dehydration 1 0.5% 4 1.9% 12 5.6% 0 0.0% 0 0.0% 
Nervous system disorders                     
Extrapyramidal disorder 0 0.0% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Peripheral sensory neuropathy 1 0.5% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Renal and urinary disorders                     
Acute kidney injury 0 0.0% 0 0.0% 1 0.5% 0 0.0% 0 0.0% 
Chronic kidney disease  0 0.0% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Respiratory, thoracic and 
mediastinal disorders 
                    
Dyspnoea 2 0.9% 2 0.9% 0 0.0% 0 0.0% 0 0.0% 
Skin                     
Alopecia 1 0.5% 1 0.5% 0 0.0% 0 0.0% 0 0.0% 
Vascular disorders                     
Thromboembolic event 9 4.2% 10 4.7% 4 1.9% 0 0.0% 0 0.0% 
 
 
Table 3 - Univariable and multivariable cox regression analysis of overall survival (OS) by baseline 
characteristics in all patients (N=214) 
    OS (months)** Univariable Multivariable (n=195) 
    n Median 95% CIs HR 95% CIs p HR 95% CIs p 
Age  
<75 129 20.5 (18.0, 27.0) 1.00     1.00    
≥75 85 28.9 (21.0, -) 0.63 (0.38, 1.05) 0.077 0.65 (0.37, 1.17) 0.366 
Sex 
Female 75 32.1 (16.9, -) 1.00     1.00     
Male 139 24.0 (20.0, 28.9) 1.08 (0.66, 1.77) 0.748 1.06 (0.58, 1.91) 0.858 
WHO PS  
0 62 28.9 (18.0, -) 1.00     1.00     
1-2 147 24.3 (19.2, 32.1) 1.08 (0.66, 1.75) 0.770 1.30 (0.73, 2.32) 0.370 
T stage 
1-2 56 - (19.2, -) 1.00     1.00     
3-4 153 22.6 (18.5, 30.1) 1.69 (0.93, 3.09) 0.086 1.03 (0.52, 2.04) 0.926 
N stage 
0 97 28.9 (24.0, -) 1.00     1.00     
1+ 117 20.5 (17.8, 24.3) 2.01 (1.20, 3.36) 0.008 1.78 (0.95, 3.34) 0.074 
Induction 
chemo 
N 132 28.8 (22.6, 33.4) 1.00     1.00     
Y 82 19.2 (16.7, 24.3) 1.63 (1.03, 2.56) 0.037 1.53 (0.89, 2.65) 0.126 
Histology 
Squamous cell 
carcinoma(SCC) 
91 32.1 (18.0, -) 1.00     1.00     
Adenocarcinoma 123 22.6 (20.0, 28.9) 1.09 (0.69, 1.73) 0.713 1.05 (0.53, 2.05) 0.891 
Site 
Mid Third/ 
Upper Third 
91 32.1 (18.0, -) 1.00     1.00     
Lower Third 123 24.0 (20.1, 28.9) 1.10 (0.69, 1.74) 0.698 0.91 (0.48, 1.74) 0.782 
Indication 
for 
Carboplatin/ 
Paclitaxel 
Non-progressors  196 24.3 (20.1, 30.1) 1.00     1.00     
Progressors 17 - (8.1, -) 1.12 (0.51, 2.44) 0.783 0.53 
(0.20, 1.44) 0.213 
Disease length - mean (sd) 
4.91 
(2.27) 
    1.13 (1.02, 1.26) 0.021 1.11 (0.99, 1.26) 0.085 
*HRs calculated for every 1cm increase 
**From diagnosis 
Table 4 – Univariable and multivariable cox regression analysis of overall survival (OS) by baseline 
characteristics in patients that reached and received the post treatment endoscopy (N=139) 
    OS (months)** Univariable Multivariable (n=124) 
    n Median 95% CIs HR 95% CIs p HR 95% CIs p 
Age  
<75 83 24.3 (18.0,-) 1.00     1.00    
≥75 56 28.9 (21.0,-) 0.73 (0.37,1.44) 0.358 1.09 (0.48,2.47) 0.829 
Sex 
Female 47 33.7 (16.9,-) 1.00     1.00     
Male 92 27.0 (20.5,-) 1.03 (0.52,2.05) 0.926 1.48 (0.58,3.75) 0.411 
WHO PS  
0 46 28.9 (20.1,-) 1.00     1.00     
1-2 89 27.0 (21.0,-) 1.12 (0.58,2.16) 0.743 1.47 (0.59,3.65) 0.412 
T stage 
1-2 41 - (20.1,-) 1.00     1.00     
3-4 93 24.3 (20.5,33.7) 1.69 (0.74,3.88) 0.215 0.92 (0.36,2.34) 0.854 
N stage 
0 70 28.9 (20.1,-) 1.00     1.00     
1+ 69 24.3 (18.0,33.7) 1.70 (0.86,3.38) 0.130 1.08 (0.45,2.62) 0.863 
Induction 
chemo 
N 89 28.8 (24.3,-) 1.00     1.00     
Y 50 20.5 (16.9,33.7) 1.86 (1.00,3.55) 0.060 1.33 (0.60,2.97) 0.487 
Histology 
Squamous cell 
carcinoma(SCC) 
56 - (18.5,-) 1.00     1.00     
Adenocarcinoma 83 27.0 (20.5,33.7) 0.95 (0.50,1.82) 0.879 0.53 (0.19,1.43) 0.208 
Site 
Mid Third/ 
Upper Third 
56 - (18.5,-) 1.00     1.00     
Lower Third 83 27.0 (20.5,33.7) 1.09 (0.57,2.08) 0.802 0.95 (0.36,2.45) 0.909 
 
Post 
treatment 
Response  
CR (endoscopy) 
& CR/SD/PR 
(imaging) 
98 30.1 (27.0,-) 1.00     1.00     
Others 41 16.9 (14.2,22.6) 3.86 (2.04,7.33) <0.001 5.07 (2.11,12.21) <0.001 
Disease length* - mean (sd) 
4.71 
(2.13) 
    1.10 (0.94,1.29) 0.231 1.05 (0.86,1.28) 0.659 
*HRs calculated for every 1cm increase 
**From diagnosis 
 
 
 
 
Discussion 
This UK multicentre retrospective cohort evaluated the outcome of wCP based dCRT in ‘borderline 
fit/risk adverse’ patients. Forty percent of the patients were 75 years or older, (18.7% ≥ 80 years), 63% 
had either significant comorbidities at baseline or had progression/intolerance to induction 
chemotherapy and nearly 60% of the patients had ACA. The median OS was 24.3 months with an 
overall Grade 3-4 toxicity rate of 33% during dCRT.  Following treatment, patients who had complete 
response (CR) on the endoscopy plus non-progression (CR/PR/SD) on imaging (“failure free”) had the 
best outcome with 1-year survival of ~92% and a 2-year survival of ~60%   
Study in the context of current literature 
 
There are no published randomised trials assessing the role of wCP chemotherapy concurrent with 
definitive radiotherapy in oesophageal cancer.  The CROSS trial utilised wCP in the neoadjuvant setting 
and demonstrated that this combination was well tolerated, with low haematological and non-
haematological toxicity (toxicity grade 3 7% and 13% respectively), and a pathological complete 
response rate of 29%. Based on these results several retrospective studies have assessed this 
combination in the definitive setting.  Table 5 provides a comparison with other reported studies. Prior 
to our series, the largest retrospective study by Versteijne et alvi included 184 patients and demonstrated 
a median OS 16.8 months. However, no acute or long term toxicity was reported in this paper and a 
quarter of patients did not complete the chemotherapy. It, however, confirmed that 41% developed 
locoregional recurrence post treatment (median follow-up 22.8 months), the majority at the site of the 
primary tumour, which is comparable to our locoregional recurrence data.  The study by Noronha et 
alvii also included a similar number (n=179) and reported a median OS of 19 months.  However, 92% 
of patients had SCC histology and only 15% of patients had tumours in the distal oesophagus/GOJ.  In 
addition, 56% of patients developed grade 3 toxicity with a high incidence of neutropenia (12%) and 
 
infection (11%).  In most of the other studies, SCC was the prevalent histology, unlike our series, where 
57% of the patients had ACA.  The only study reporting outcomes in patients with predominantly ACA 
histology was the series published by Haj Mohammed et alviii, and included 127 patients, categorised as 
either being medically inoperable due to comorbidities, or irresectable due to tumour stage.  They 
reported a median OS of 17.1 months.  The study demonstrated that toxicity (grade 3 toxicity 44%) 
and tolerance to chemotherapy was significantly worse in  medically inoperable patients compared to 
those irresectable due to tumour stage (median age 72 years).  The majority of other reported 
retrospective studies also have a younger median age of patients.  Only one small retrospective study 
by Kelly et alix assessed wCP with definitive radiotherapy in an elderly population (aged 70).  It 
confirmed that this regimen is well-tolerated although numbers were small (n=27). 
 
 
TABLE 5 SUMMARY OF PUBLISHED STUDIES 
AUTHORS Study type N Age Histology Rtx dose Toxicity OS 
OWENS ET AL 
(2019) 
Retrospective  N=214 Median age 73 42.5% SCC 50Gy in 25 
fractions 
33% ≥grade 3 
toxicity 
Median OS 24.3 
months 
WANG ET AL 
(2007)x 
Phase II N=50 Median age 60 33% SCC 45Gy in 25 
fractions 
Neutropenia 23% Median OS >44 
months (n=16) 
MEERTEN ET AL 
(2010)xi 
Phase II (abstract) N=52 Not reported 70% SCC Not reported Grade ≥ 3: 
neutropenia 16%, 
esophagitis 12%, 
fatigue 8%, 
Median OS 17 
months 
KELLY ET AL 
(2013) 
Retrospective N=27 All aged over 70 56% SCC Not reported Not reported At 11 months, 
55% alive 
VERSTEIJNE ET AL 
(2014) 
Retrospective N=184 Median age 66 52% SCC 50.4Gy in 28 
fractions 
Not reported Median OS 16.8 
months 
HAJ MOHAMMAD 
(2014) 
Retrospective N=127 Mean age 63 46% SCC 50.4Gy/28 27% grade 3 
toxicity 
Median OS 17 
months 
NORONHA ET AL 
(2016) 
Retrospective N=179 Median age 54 92% SCC Mean 58.7Gy/32 56% ≥grade 3 
toxicity 
Median OS 19 
months 
ARAUJO ET AL 
(2016)xii 
Retrospective N=46 Median age 62 83% SCC 50.4Gy in 28 
fractions 
13% fatigue Median OS 13.4 
months 
XIA ET AL (2017)xiii Phase II N=65 Mean age 61 90% SCC 50.4Gy/28 or 
61.2Gy/34 
28% ≥grade 3 
toxicity 
Median OS 21.7 
months 
VAN RULER ET AL 
(2017)xiv 
Retrospective N=66 Median age 69 59% SCC 50.4Gy in 28 
fractions 
61% adverse 
event grade ≥3 
Median OS 13.1 
months. 2 year OS 
30% 
HONING ET AL 
(2014) 
Retrospective 
(comparison to 
cis-5FU) 
N=55 Median age 65 58% SCC Median dose 50.4 
Gy 
21% ≥grade 3 
toxicity 
Median OS 13.8 
months 
QU ET AL (2017)xv Retrospective 
(comparison to 
N=26 Median age 76 35% SCC 50Gy in 25 
fraction 
38% ≥grade 3 
toxicity 
Median OS 15 
months 
 
cis/5FU or 
carbo/5FU) 
MUNCH ET AL 
(2018)xvi 
Retrospective 
(comparison to 
cis/5FU) 
N=22 Median age 68 100% SCC Median dose 
59.4Gy/33 
Myelotoxicity ≥ 
grade 3 55% 
1 year OS 70% 
 
Our study is one of the largest studies evaluating the use of wCP for dCRT in oesophageal cancer and 
the first from the UK, and demonstrates that outcomes and toxicities are consistent with current 
literature, and reproducible in a multi-centre setting. Secondly, this pragmatic study, predominantly in 
an elderly population, has selectively looked at patients who would otherwise be considered unsuitable 
for radical CRT - a patient population which we frequently encounter in day to day practice, but which 
is not well represented in clinical trials. This study assures us that survival in this patient group is 
comparable to that seen in younger/fitter patients. Thirdly, >50% of the patients had adenocarcinoma 
and >50% had distal oesophageal or junctional tumours, which is reflective of patient distribution in 
western populations. As discussed, the study by Versteijne et al, whilst comparable to our study 
population, demonstrated a median OS of 16.8 months overall with a statistically significant 
improvement in OS in squamous histology vs adenocarcinomas (20.5 months vs 14.7 months p=0.046).  
The majority of other large retrospective studies also had a significantly higher number of patients with 
squamous histology. Despite these differences and the perceived better response/survival in SCC, our 
data suggests that equivalent survival and response rates can be achieved in an ACA predominant 
population. Finally, this study lends further support to the use of 12-week post-treatment response 
criteria as a surrogate for overall survival, as originally reported in the SCOPE-1 trialxvii. Patients who 
were failure free at response evaluation had a statistically superior OS compared to those who were not 
failure free (30.1 months vs 16.9 months). Our data also demonstrated that locoregional recurrence 
occurred in 41% of patients, comparable to published studies.  The prospective ART-DECO study is 
assessing the use of weekly carboplatin-paclitaxel dCRT and randomising between standard dose 
radiotherapy (50.4Gy in 28 fractions) versus a dose escalation arm with a simultaneous integrated boost 
to the primary tumour (total dose 61.6Gy in 28 fractions).  The aim of this study is to assess if dose 
escalation will improve local tumour control and thus overall survival.  In the ongoing SCOPE2 study 
(https://clinicaltrials.gov/ct2/show/NCT02741856), patients with an inadequate Day 14 PET-CT 
response are being randomised to continuing cisplatin-capecitabine as concurrent chemotherapy versus 
switch to carboplatin-paclitaxel regimen. Radiotherapy dose escalation (50Gy/25 fractions vs 60Gy/25 
fractions) is also being evaluated in the study.  
 
Limitations 
The biggest limitation of the current study is its retrospective nature, and there is likely to be under-
reporting, particularly of toxicity data and late sequelae from treatment. The study was not randomised 
but, as discussed, prospective randomised comparison to standard cisplatin-5FU chemotherapy is 
unlikely to be assessed in the future due to the perceived equipoise of the two regimens.   Although we 
aimed to include ‘high risk’ patients only, an element of selection bias is inevitable. Notably, 36% of 
the patients received this treatment as “clinician choice” suggesting decisions regarding fitness may 
 
have been made subjectively in a proportion of patients although as noted, survival of this patient group 
was not significantly different to others.  Geriatric assessment tools are not routinely used in assessment 
of elderly cancer patients, but with increasing life expectancy and the increasing treatment options in 
oncology, onco-geriatric assessments need to become integral part of cancer care.  Indeed, the phase I-
II OSAGE trial specifically aims to look at outcomes from wCP dCRT in the over-75 patient group, 
and incorporates formal geriatric evaluationxviii.   
Another short-coming is the relatively short follow-up (median FU alive patients of 16.89 months). 
However, this is similar to the median follow up in the initial report from the SCOPE-1 trial (16.8 
months), and shows comparable outcomes at this data point (median OS 25.4 months vs 24.3 months). 
The proportion of patients who were treatment failure free at 12 weeks post treatment was 76.9% in 
SCOPE1 and 72.1% in the cohort reported here. However, reported grade 3/4 toxicities in the dCRT 
arm in SCOPE-1, were significantly higher (28% haematological toxicity and 63% non-haematological) 
although this data was prospectively gathered in comparison to our study. 
Conclusion 
Weekly carboplatin-paclitaxel based chemoradiotherapy appears to be well tolerated in elderly patients 
and in those with co-morbidities, where CF-based dCRT is not appropriate. Treatment outcomes are 
promising and support the use of this regimen in clinical practice. Outcomes from prospective trials are 
awaited and, pending regulatory approval, the use of weekly carboplatin-paclitaxel is being 
incorporated as one of the study arms in the prospective SCOPE-2 trialxix albeit in a select patient group 
(non-responders at day 14 PET/CT assessment).      
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